SE9601091D0 - The use of a protein substance to bind steroid-like molecules - Google Patents

The use of a protein substance to bind steroid-like molecules

Info

Publication number
SE9601091D0
SE9601091D0 SE9601091A SE9601091A SE9601091D0 SE 9601091 D0 SE9601091 D0 SE 9601091D0 SE 9601091 A SE9601091 A SE 9601091A SE 9601091 A SE9601091 A SE 9601091A SE 9601091 D0 SE9601091 D0 SE 9601091D0
Authority
SE
Sweden
Prior art keywords
bile
treatment
beneficial
injury
bile acids
Prior art date
Application number
SE9601091A
Other languages
Swedish (sv)
Other versions
SE9601091L (en
Inventor
Joyce Carlson
Sabina-Marija Janciauskiene
Original Assignee
Joyce Carlson
Sabina Marija Janciauskiene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joyce Carlson, Sabina Marija Janciauskiene filed Critical Joyce Carlson
Priority to SE9601091A priority Critical patent/SE9601091L/en
Publication of SE9601091D0 publication Critical patent/SE9601091D0/en
Priority to EP97914726A priority patent/EP0904102A1/en
Priority to AU21864/97A priority patent/AU2186497A/en
Priority to PCT/SE1997/000465 priority patent/WO1997034628A1/en
Publication of SE9601091L publication Critical patent/SE9601091L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Abstract

The use of human alpha 1-antitrypsin as a foodstuff or as a medicament, utilizing its capacity to bind steroids and steroid-like substances, and transporting them in biological systems is described. Particularly the direct oral administration of the milk of transgenic animals containing abundant amounts (10-60 g/L) of human alpha 1-AT to reinstate a defect intestinal synthesis or to complement the normal physiological biosynthesis of alpha 1-AT is described. Such treatment will reduce the total body load of bile acids by increasing their gastrointestinal elimination. It is expected to be beneficial for bile acid related diseases such as all cholestatic liver diseases, and bile-reflux gastritis. Such treatment is expected to be particularly beneficial in cases of neonatal cholestasis, as newborns circulate large quantities of hydrophobic bile acids which cause liver injury and may contribute to injury of other tissues. It will be protective in cases where bile acids cause tissue injury such as vasculitis, glomerulonephritis, and inflammatory bowel disease. It will be beneficial against diarrhoea in intestinal bacterial overgrowth and bile acid malabsorption. Increased gastrointestinal elimination of the steroid structure may also reduce the total body load of cholesterol and thus be efficient in the treatment of hyperlipidemia.
SE9601091A 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules SE9601091L (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9601091A SE9601091L (en) 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules
EP97914726A EP0904102A1 (en) 1996-03-21 1997-03-20 Milk of transgenic animals containing human alpha 1-antitrypsin and use of human alpha 1-antitrypsin to treat bile acid related diseases
AU21864/97A AU2186497A (en) 1996-03-21 1997-03-20 Milk of transgenic animals containing human alpha1-antitrypsin and use of human alpha1-antitrypsin to treat bile acid related diseases
PCT/SE1997/000465 WO1997034628A1 (en) 1996-03-21 1997-03-20 Milk of transgenic animals containing human alpha1-antitrypsin and use of human alpha1-antitrypsin to treat bile acid related diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601091A SE9601091L (en) 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules

Publications (2)

Publication Number Publication Date
SE9601091D0 true SE9601091D0 (en) 1996-03-21
SE9601091L SE9601091L (en) 1997-09-22

Family

ID=20401887

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9601091A SE9601091L (en) 1996-03-21 1996-03-21 Use of a protein substance for the binding of steroid-like molecules

Country Status (4)

Country Link
EP (1) EP0904102A1 (en)
AU (1) AU2186497A (en)
SE (1) SE9601091L (en)
WO (1) WO1997034628A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940700D1 (en) * 1998-11-19 2009-05-20 Pharming Intellectual Pty Bv STABILIZATION OF MILK TRANSGENER PETS
US7030289B2 (en) 1998-11-19 2006-04-18 Ppl Therapeutics (Scotland) Ltd Stabilization of milk from transgenic animals
WO2000044390A1 (en) * 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
AUPP971399A0 (en) * 1999-04-12 1999-05-06 Life Therapeutics Limited Separation of plasma components
JPWO2009008120A1 (en) * 2007-07-12 2010-09-02 杉山　雄一 Membrane protein stabilizer and stabilization method
CN108697704A (en) 2016-02-22 2018-10-23 诺华股份有限公司 Use the method for FXR agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439824A (en) * 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II

Also Published As

Publication number Publication date
EP0904102A1 (en) 1999-03-31
WO1997034628A1 (en) 1997-09-25
AU2186497A (en) 1997-10-10
SE9601091L (en) 1997-09-22

Similar Documents

Publication Publication Date Title
Morita et al. Resistant proteins alter cecal short-chain fatty acid profiles in rats fed high amylose cornstarch
Russel Elemental diets.
Booth et al. Studies on the site of fat absorption: 2 Fat balances after resection of varying amounts of the small intestine in man
Dahlqvist et al. The digestion and absorption of sucrose by the intact rat
NO20063328L (en) Use of a fatty acid composition comprising at least one of EPA and DHA or combinations thereof
Kramer et al. The effect of specific foods and water loading on the ileal excreta of ileostomized human subjects
BRPI0611020A2 (en) use of polydextrose to stimulate functional attributes of human milk oligosaccharides in formula-fed young children
Malyugina et al. The Practicability of the Application of Vitamin D in Combination with Vitamin C for the Improvement of Bone Tissue Metabolism.
Gausserès et al. [15N]-labeled pea flour protein nitrogen exhibits good ileal digestibility and postprandial retention in humans
SE9601091D0 (en) The use of a protein substance to bind steroid-like molecules
McCollum et al. The" vitamine" hypothesis and deficiency diseases: a study of experimental scurvy
Van De Heijning et al. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones
JP4383165B2 (en) Nutritional composition to prevent bacterial overgrowth
Shintani et al. D-Allose, a trace component in human serum, and its pharmaceutical applicability
Verdegem et al. Effect of dietary NSP level and bile acid supplementation on nutrient digestibility and the bile acid metabolism in rainbow trout (Oncorhynchus mykiss)
Strandvik et al. The urinary bile acid excretion in healthy premature and full-term infants during the neonatal period
Roberton et al. Biliary control of β-glucuronidase activity in the luminal contents of the rat ileum, cecum, and rectum
ES2913336T3 (en) Methods of using secretory IgA
Gandarillas et al. The domestic pig (Sus scrofa domestica) as a model for evaluating nutritional and metabolic consequences of bariatric surgery practiced on morbid obese humans
Guilford New ideas for the dietary management of gastrointestinal tract disease
Chinery et al. Soy polysaccharide in an enteral diet: effects on rat intestinal cell proliferation, morphology and metabolic function
Fåk et al. Age-related effects of the probiotic bacterium Lactobacillus plantarum 299v on gastrointestinal function in suckling rats
KR100484326B1 (en) Foods containing cocoa component
Zaiets et al. CHARACTERISTICS OF BILIGENIC FUNCTION OF LIVER IN RESPONSE TO CRANIO-SKELETAL TRAUMA COMPLICATED BY HAEMORRHAGE
Yang et al. Insulin with chondroitinase ABC treats the rat model of acute spinal cord injury

Legal Events

Date Code Title Description
NAV Patent application has lapsed